Intratumoral Cancer Therapies Market Report 2025

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $140 billion in 2024 to $158.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $248.42 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies.

The rising incidence of cancer is anticipated to drive the growth of the intratumoral cancer therapies market in the future. Cancer refers to a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells within the body. Intratumoral cancer therapies are utilized in the diagnosis and treatment of cancer, helping to mitigate off-target toxicities, dose-limiting toxicities, and adverse effects associated with immune stimulation in patients with cancer. For example, in January 2023, the American Cancer Society, a US-based nonprofit organization dedicated to cancer advocacy, reported that the number of cancer cases reached 1,958,310 in 2023, marking a 3.16% increase from 1,898,160 in 2021. Thus, the rising incidence of cancer is fueling the growth of the intratumoral cancer therapies market.

The increasing integration of immunotherapy is expected to further accelerate the growth of the intratumoral cancer therapies market in the coming years. Immunotherapy is a type of cancer treatment that utilizes substances produced by the body or created in a laboratory to enhance the immune system and assist the body in locating and destroying cancer cells. Intratumoral therapies align with the growing emphasis on immunotherapy, offering a localized and effective approach to modulating the immune response within the tumor microenvironment. For instance, in June 2022, the United States Food and Drug Administration (FDA), a federal agency of the US Department of Health and Human Services, approved 35 immune checkpoint inhibitor (ICI)-based combination immunotherapies in 2022. Consequently, the rise in immunotherapy integration is driving the growth of the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical company focused on the research, commercialization, and discovery of prescription medications for oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition will create new opportunities for AstraZeneca in the field of cancer treatment. Neogene Therapeutics Inc. is a Netherlands-based biotechnology research firm that provides personalized therapies based on TCR genes that specifically target neoantigens found in a patient's tumor.

Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC.

North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intratumoral cancer therapies involve treatments directly administered or applied to a tumor. These therapies are specifically crafted to target tumor cells and can be employed in conjunction with other cancer treatments, such as chemotherapy and radiation therapy.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.